INMB News and Press, INmune Bio Inc. From 02/08/23

BOCA RATON, Fla., Feb. 08, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces that it has re...

Summary The treatment of Moderate Alzheimer's disease requires intervention after the over-activation of NMDA receptors. BioVie does this by reducing the phosphorlyation of ERK (Extracellular Regulatory Kinase) and by inhibiting NF-kB (Nuclear Factor-kappa Beta). Panax ginseng does ...

Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in collaboration with Pro...

Summary INmune Bio has multiple potential catalysts ahead including the go-ahead to start Phase 2 trials with XPro in the US. The company will soon file an IND for its immunotherapy candidate INKmune in a solid tumor indication, which I believe may garner investor and analyst interest. ...

XPro1595 decreases development of amyloid beta and tau following TBI in murine model of Alzheimer’s disease Boca Raton, Florida, Dec. 22, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology compan...

Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to...

Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer. Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th annual San Antonio Breast Cancer Symposium today Boca Raton, Florid...

Summary BioVie’s NE3107 has now shown improvement of cognition and function on different Alzheimer’s rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo-controlled trial in Parkinson’s disease with the same dru...

INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15 th CTAD conference in San Francisco November 29th to December 2 nd Boca Raton, Florida, Nov. 29, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. ...

INmune Bio ( NASDAQ: INMB ) said on Monday that Health Canada had issued a no objection letter to begin  trial of XPro1595 to treat mild Alzheimer’s Disease in Canada. "We are pleased that Canada is now part of this international Phase II trial,&#...